BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Beam Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$24.19+0.72 (+3.07%)

Close on Oct 19, 2026

Market cap: $2.52B
P/E (TTM): –
Dividend yield: –

Beam Therapeutics Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Cash & Equivalents	295	290	436	246	573	177	51	148
Short-Term Investments	950	569	754	845	–	138	–	–
Cash & Short-Term Investments	1,200	851	1,200	1,100	966	300	51	148
Prepaid Expenses & Other	23	27	21	15	7.36	8.65	2.70	–
Total Current Assets	1,269	878	1,211	1,093	1,273	308	95	–
Property, Plant & Equipment	105	111	125	116	84	39	24	–
Gross Property, Plant & Equipment	199	184	175	146	100	47	28	–
Accumulated Depreciation	-94	-72	-50	-30	-16	-8.90	-4.16	–
Long-Term Investments	–	–	–	–	–	2.58	–	–
Equity Method Investments	–	0	0	0	–	–	–	–
Operating Lease Right-of-Use Assets	101	105	113	119	103	87	19	–
Other Long-Term Assets	0.63	1.25	2.15	1.93	1.72	3.14	4.98	–
Total Assets	1,481	1,104	1,460	1,342	1,474	452	156	–
Accounts Payable	10	3.87	1.62	9.03	7.47	6.31	7.85	–
Current Portion of Leases	14	13	13	10	7.54	4.22	4.34	–
Deferred Revenue (Current)	6.66	109	69	136	86	0.02	–	–
Total Current Liabilities	97	182	206	224	213	102	29	–
Long-Term Leases	140	148	160	169	135	96	21	–
Operating Lease Liabilities	154	161	173	179	142	100	26	–
Other Long-Term Liabilities	0.17	0.50	0.30	1.38	2.79	2.08	0.42	–
Total Liabilities	243	370	478	608	648	206	55	–
Common Stock	1.02	0.84	0.82	0.71	0.68	0.57	0.07	–
Additional Paid-In Capital	2,877	2,299	2,170	1,793	1,594	643	1.85	–
Retained Earnings	-1,641	-1,567	-1,190	-1,057	-768	-398	-203	–
Comprehensive Income & Other	1.11	0.68	0.60	-2.43	-0.05	-0.01	0.02	–
Shareholders' Equity	1,238	734	981	733	827	246	-201	-117
Total Equity	1,238	734	981	733	827	246	-201	-117
Total Liabilities & Equity	1,481	1,104	1,460	1,342	1,474	452	156	–
Shares Outstanding(shares)	102	84	82	71	68	57	7.33	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -242.3%
Net margin: -54.7%
Return on equity, FY2025: -8.1%

Financial strength

Current ratio: 14.57
Debt to equity: 0.09
Debt to assets: 7.2%
Cash to current liabilities: 271.8%

Valuation

P/E ratio: –
Price to sales: 16.17
Price to book: 2.36
Dividend yield: –